You are here: Industry Insights > Johnson & Johnson

News List

J&J begins human trials of COVID-19 vaccine expresspharma
August 03, 2020
It will test its vaccine candidate in more than 1,000 healthy adults aged 18 to 55 years, as well as adults aged 65 years and older.
J&J’s Lead COVID-19 Vax Candidate Elicits Immune Response contractpharma
July 31, 2020
Preclinical data shows adenovirus serotype 26 vector-based vaccine elicited a robust immune response as demonstrated by neutralizing antibodies.
J&J in talks with Japan, Gates Foundation to lock in deals on COVID-19 vaccine expresspharma
July 17, 2020
J&J has already agreed to prioritize an allocation to the United States as part of its funding agreement with the U.S. government’s Biomedical Advanced Research and Development Authority.
J&J drops TB drug price following mass petition expresspharma
July 08, 2020
Médecins Sans Frontières insisted that prices should come further down from the revised price of the drug, bedaquiline, hailed as the backbone of DR-TB treatment by WHO.
J&J Accelerates COVID-19 Vaccine Candidate americanpharmaceuticalreview
June 22, 2020
Johnson & Johnson announced through Janssen Pharmaceutical, it has accelerated the initiation of the Phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant.
J&J accelerates clinical trial of investigational COVID-19 vaccine europeanpharmaceuticalreview
June 15, 2020
The investigational SARS-CoV-2 vaccine developed by J&J is now due to start its Phase I/IIa clinical trial at the end of July.
Johnson & Johnson announces acceleration of its COVID-19 vaccine candidate; Phase 1/2a clinical trial to begin in second half of July worldpharmanews
June 11, 2020
Johnson & Johnson announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant.
J&J signs Covid-19 vaccine manufacturing contract with Vibalogics pharmaceutical-technology
May 20, 2020
Johnson & Johnson (J&J) has signed a deal with contract development and manufacturing organisation (CDMO) Vibalogics for the manufacture of clinical trial material for a Covid-19 vaccine candidate being developed by J&J unit Janssen Pharmaceutical.
J&J selects Emergent BioSolutions for Covid-19 vaccine manufacturing pharmaceutical-technology
April 26, 2020
Johnson & Johnson (J&J) subsidiary Janssen Pharmaceutical has signed an agreement with Emergent BioSolutions for manufacturing services for its lead investigational Covid-19 vaccine candidate.
J&J strikes deal with Emergent BioSolutions on coronavirus vaccine manufacturing expresspharma
April 24, 2020
Under the deal, valued at about $135 million, Emergent said it would provide drug substance manufacturing services and was reserving large-scale manufacturing capacity.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page